An effective curative therapy for Alzheimer's disease is approved by a major regulator before 2035.
Current Alzheimer's treatments slow progression rather than reversing or curing neurodegeneration. Resolution requires approval of a therapy that halts and reverses cognitive decline in diagnosed patients.
Across 6 frontier models answering independently, the panel has all but ruled it out: the median is 6%.
They broadly agree, 16 points between GPT at 18% and Qwen at 2%.
Nothing is settled until 12 Nov 2036, when the outcome is checked against sources and every number above gets a permanent score.
What each one said
-
GPTOpenAI
It hinges on whether a disease-modifying mechanism can show durable cognitive reversal in large Phase 3 trials by 2034.
- FDA, EMA, or another major regulator would need pivotal evidence of halted and reversed decline, not merely biomarker clearance.
- Alzheimer’s drug trials typically require 3–6 years from Phase 2 through approval; no current late-stage program has established reversal.
- Approval of a replicated regenerative or tau-targeting therapy with sustained cognitive gains by 2031 would materially raise the odds.
18% -
DeepSeekDeepSeek
A true cure needs a mechanism that reverses existing neurodegeneration, not just slows amyloid or tau pathology.
- Lecanemab and donanemab cleared amyloid yet only slowed decline ~27-35%, so the amyloid hypothesis has not delivered reversal.
- Anti-amyloid antibodies took 20+ years from target validation to approval; a curative mechanism is not yet in Phase 3.
- The 2035 deadline gives ~9 years, but a Phase 3 reversal trial plus FDA review typically needs 8-12 years from discovery.
12% -
GrokxAI
Turns on a late-stage trial showing actual cognitive restoration (not slowing) plus regulator approval by end-2034.
- No current pipeline asset (anti-amyloid/tau/inflammation) has shown reversal; neuronal regeneration remains unproven in humans.
- Median discovery-to-approval is 12+ years; nothing in phase 3 for restoration now, so an 8-year path sits far below base rate.
- A positive phase-2 restoration signal by 2028 would be the single development that most raises this probability.
8% -
GeminiGoogle
Reversing established neurodegeneration requires cellular repair that has never succeeded in late-stage clinical trials.
- A 2035 regulatory approval requires candidate drugs demonstrating cognitive reversal in Phase 2 trials right now, but none exist.
- FDA and EMA have historically accepted modest slowing of decline; no approved drug has ever reversed structural brain atrophy.
- Proven neurogenesis and synaptogenesis therapies crossing the blood-brain barrier remain stuck in preclinical rodent models.
4% -
ClaudeAnthropic
No drug in late-stage trials reverses established neurodegeneration; this needs a biology breakthrough plus a decade-long approval path.
- Current approved drugs (lecanemab, donanemab) only modestly slow decline, not reverse it, showing the field's current ceiling.
- A true curative/reversal therapy would require novel mechanisms (e.g. regeneration or protein clearance with functional recovery) not yet validated even in Phase 2.
- Drug development timelines from first human proof-of-concept to approval typically run 10-15 years, leaving little margin before 2035.
4% -
QwenAlibaba
No therapy in any trial phase has shown reversal of cognitive decline; the biology requires neuroregeneration we cannot yet deliver.
- Zero curative therapies exist for any neurodegenerative disease; even lecanemab/donanemab only slow decline ~30%, and no Phase 2/3 candidate shows reversal.
- A therapy entering Phase 3 today needs ~5-7 years to approval, and no candidate demonstrating cognitive improvement (not just slowed loss) is currently in Phase 2.
- Reversal requires replacing dead neurons or restoring lost synapses at scale—a capability with no proven human mechanism; a Phase 2 result showing actual cognitive gain…
2%
6 of 6 models answered · 16 points between the highest and lowest. None was shown the market price.
Question sourced from a news sweep on 15 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.